China’s SciClone Pharmaceuticals (6600.HK) has begun a clinical trial to test if its hepatitis B treatment Zadaxin helps to boost immunity provided by COVID-19 vaccines, it said on Monday.

SciClone said it is using an inactivated COVID-19 vaccine in its trial but did not specify which one. Three coronavirus vaccines approved in China use inactivated virus and have been developed by China National Pharmaceutical Group (Sinopharm) and Sinovac Biotech (SVA.O).

“In view of the mechanism of action of Thymalfasin (Zadaxin) and previous clinical studies, the combination with Thymalfasin may help increase the level of SAR-Cov-2 neutralizing antibody and prolong the antibody protection time,”

Read More At Article Source | Article Attribution